Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial

Fig. 1

a Study design and (b) disposition of participants. aOne participant withdrew consent on day 19 (last treatment on day 16); an additional participant was randomised as a replacement. bOne participant withdrew consent owing to personal reasons between randomisation and treatment initiation on day 1; an additional participant was randomised as a replacement. cReceived all planned treatments before being lost to follow-up. dOnly 11 of the 12 planned patients with T2DM were enrolled owing to difficulties in recruiting individuals who met all inclusion/exclusion criteria. PD pharmacodynamic; T2DM type 2 diabetes mellitus

Back to article page